Stock Analysis on Net
Stock Analysis on Net

Eli Lilly & Co. (NYSE:LLY)

Common-Size Balance Sheet: Liabilities and Stockholders’ Equity 
Quarterly Data

Eli Lilly & Co., common-size consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

Microsoft Excel
Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Short-term borrowings and current maturities of long-term debt 2.74 7.18 2.58 10.79 3.88 1.21 0.01 3.03 3.68 4.51 2.89 3.15 3.24 3.72 0.01 0.02 1.34 3.01 7.90 3.82 4.13 5.35 6.20
Accounts payable 3.82 4.07 3.87 4.06 4.20 4.51 3.79 3.90 3.55 3.53 3.05 3.42 3.25 3.34 3.50 3.45 3.25 2.97 2.94 3.58 2.94 3.10 3.07
Employee compensation 2.25 1.63 1.32 2.58 2.13 1.58 1.39 2.14 2.07 1.78 1.48 1.96 1.74 1.58 1.39 2.14 1.81 1.61 1.38 2.33 1.86 1.52 1.35
Sales rebates and discounts 16.44 17.32 14.75 18.26 19.90 18.95 17.93 17.75 18.05 16.98 14.43 14.03 14.91 14.72 12.43 12.55 13.07 12.59 11.44 12.56 13.93 12.91 11.72
Dividends payable 0.00 1.63 0.00 1.83 0.00 1.85 0.00 2.06 0.00 1.87 0.00 1.81 0.00 1.61 0.00 1.65 0.00 0.00 0.00 1.71 0.00 1.54 0.00
Other current liabilities 7.38 5.91 6.57 5.13 7.88 6.40 7.00 5.75 5.63 4.53 6.68 6.46 5.25 6.60 7.68 6.96 7.78 8.39 7.02 5.98 5.72 6.24 7.22
Current liabilities 32.63% 37.73% 29.09% 42.64% 37.98% 34.51% 30.11% 34.63% 32.98% 33.19% 28.53% 30.84% 28.39% 31.57% 25.01% 26.77% 27.25% 28.57% 30.68% 29.97% 28.58% 30.66% 29.56%
Long-term debt, excluding current maturities 38.42 33.02 38.41 28.62 30.95 33.13 35.51 29.78 29.80 31.22 32.30 31.44 32.21 30.82 34.59 35.57 37.17 35.90 34.02 35.17 36.05 35.48 35.81
Accrued retirement benefits 1.92 1.98 2.23 2.25 2.27 2.39 2.47 2.64 3.86 4.01 4.14 4.00 8.05 8.20 8.48 8.78 7.82 8.10 8.84 9.41 6.37 7.04 7.26
Long-term income taxes payable 5.13 4.86 6.55 6.01 5.99 6.08 7.23 7.50 7.67 7.56 8.48 8.03 7.82 7.82 8.36 8.23 7.72 8.05 8.81 9.18 9.31 9.01 9.89
Other noncurrent liabilities 2.96 3.44 3.55 3.50 3.29 3.56 3.43 3.69 4.27 5.62 6.39 6.92 7.02 7.65 8.41 8.16 8.67 9.21 9.88 9.39 10.55 10.41 10.73
Noncurrent liabilities 48.42% 43.29% 50.74% 40.39% 42.49% 45.15% 48.64% 43.60% 45.60% 48.41% 51.30% 50.40% 55.10% 54.49% 59.83% 60.74% 61.38% 61.25% 61.54% 63.16% 62.29% 61.95% 63.69%
Total liabilities 81.06% 81.03% 79.83% 83.03% 80.48% 79.66% 78.75% 78.23% 78.58% 81.60% 79.83% 81.24% 83.49% 86.06% 84.84% 87.51% 88.63% 89.82% 92.22% 93.13% 90.86% 92.61% 93.25%
Common stock 0.79 0.83 0.93 0.93 1.02 1.08 1.12 1.20 1.25 1.26 1.27 1.22 1.24 1.25 1.28 1.28 1.36 1.43 1.46 1.52 1.58 1.56 1.60
Additional paid-in capital 9.71 10.04 10.96 11.33 12.36 12.68 12.78 13.99 14.39 14.33 14.19 14.00 14.02 13.95 14.05 14.54 15.24 15.80 15.95 17.02 17.44 16.90 15.15
Retained earnings 18.02 18.33 19.63 16.11 17.80 18.92 20.01 20.29 21.08 18.18 19.97 18.36 20.00 17.84 19.60 16.79 16.28 15.77 14.30 12.52 13.15 11.17 12.84
Employee benefit trust -3.99 -4.19 -4.71 -4.71 -5.20 -5.50 -5.67 -6.09 -6.35 -6.40 -6.42 -6.17 -6.25 -6.30 -6.43 -6.46 -6.86 -7.18 -7.33 -7.67 -7.95 -7.79 -7.93
Accumulated other comprehensive loss -5.65 -6.09 -6.72 -6.76 -6.54 -6.91 -7.11 -7.77 -9.05 -9.11 -9.01 -8.90 -12.81 -13.15 -13.65 -13.93 -14.92 -15.92 -16.75 -16.61 -15.13 -14.48 -14.96
Cost of common stock in treasury -0.04 -0.05 -0.05 -0.07 -0.08 -0.08 -0.08 -0.10 -0.11 -0.11 -0.11 -0.11 -0.11 -0.11 -0.11 -0.12 -0.13 -0.13 -0.14 -0.15 -0.16 -0.16 -0.16
Total Eli Lilly and Company shareholders’ equity 18.83% 18.87% 20.04% 16.83% 19.37% 20.18% 21.05% 21.52% 21.22% 18.16% 19.89% 18.40% 16.10% 13.48% 14.73% 12.10% 10.98% 9.75% 7.49% 6.64% 8.93% 7.19% 6.53%
Noncontrolling interests 0.11 0.10 0.13 0.14 0.15 0.16 0.20 0.25 0.20 0.24 0.28 0.36 0.41 0.46 0.43 0.39 0.38 0.43 0.29 0.23 0.21 0.20 0.22
Total equity 18.94% 18.97% 20.17% 16.97% 19.52% 20.34% 21.25% 21.77% 21.42% 18.40% 20.17% 18.76% 16.51% 13.94% 15.16% 12.49% 11.37% 10.18% 7.78% 6.87% 9.14% 7.39% 6.75%
Total liabilities and equity 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%

Based on: 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Eli Lilly & Co. current liabilities as a percentage of total liabilities and equity increased from Q1 2024 to Q2 2024 but then slightly decreased from Q2 2024 to Q3 2024 not reaching Q1 2024 level.
Noncurrent liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Eli Lilly & Co. noncurrent liabilities as a percentage of total liabilities and equity decreased from Q1 2024 to Q2 2024 but then increased from Q2 2024 to Q3 2024 not reaching Q1 2024 level.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Eli Lilly & Co. total liabilities as a percentage of total liabilities and equity increased from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024.
Total Eli Lilly and Company shareholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Eli Lilly & Co. total Eli Lilly and Company shareholders’ equity as a percentage of total liabilities and equity decreased from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024.